Efficacy and Safety of the CG-100 Intraluminal Bypass Device

Ki vehet részt

• The patient is willing to comply with protocol-specified follow-up evaluations
• Patient 22-65 years of age at screening, or patient 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed
• Patient is diagnosed with colorectal cancer
• Patient is scheduled for elective either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis, maximally 10 cm from the anal verge
• Patients who are scheduled to receive a protective stoma under routine clinical practice during their primary planned operation
• Patient is scheduled to undergo mechanical bowel preparation
• The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB)

Ki nem vehet részt

• Major surgical or interventional procedures within 45 days prior to this study or planned surgical or interventional procedures within 6 months of entry into this study (not including, placement of port for chemotherapy or ureter stent insertion)
• Patient is going through another surgical procedure (other than ileostomy, adhesiolysis) during the surgery
• The patient is currently participating in another investigational drug or device study unless pre-approved by the sponsor
• Patient has been taking regular systemic/ steroid medication in the last 6 months
• Patient has evidence of extensive local disease in the pelvis or has undergone a prior pelvic anastomosis
• Pregnant or nursing female patients. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test
• Patient has local or systemic infection at the time of intervention (e.g., peritonitis)
• Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease
• Any condition or abnormality which in the opinion of the investigator may jeopardize the patient's safe participation or the quality of the data
• Albumin < 30 g/liter
• Patients with ASA classification > 3
• Patients has a diagnosis of coagulopathy, thrombocytopenia, immune suppression
• BMI ≥ 40
• Patients is taking antimetabolites or antiplatelet agents
• Patient has preexisting sphincter problems
• Patients with massive diverticulosis at the sigmoid/descending colon (viewed on preoperative CT)